Abstract: The invention provides a method for enhanced genome engineering using CRISPR/Cas system tethered to exonucleases via different systems. By connecting Cas9 and exonucleases via heterodimeric peptides that form coiled-coils or via heterodimerization systems, greater indel mutations at desired genomic region occurs, resulting in higher genome editing rate. This novel improved CRISPR/Cas system can be exploited in different cell origins and organisms in various fields, where genome engineering is required and desired.

Abstract: The invention refers to a split superantigen, divided into two fragments that by itself do not exhibit biologic activity, only upon dimerization they regain T cell activity. Scope of the invention is a screening method for detection of effective split superantigen designs, where split superantigen fragments are fused with coiled-coil forming peptides. The present invention relates to the field of cancer immunology. Each split superantigen fragment is fused with antibody or other tumor antigen specific protein, therefore only upon the binding of split superantigen-antibody fusion proteins to the tumor antigen, split superatigen fragments comes to proximity and reconstitute into biologically active form that activates T-cell response.

Abstract: The present invention provides a therapeutic device that comprises of mixture of cells secreting combination of therapeutic proteins, where cells producing therapeutic proteins are sealed in container which enables the exchange of nutrient and therapeutic proteins. The cells inside the therapeutic device produce and secrete certain amounts of therapeutic proteins. Cells are prepared by introducing genes encoding therapeutic proteins under the control of a constitutive or inducible promoter. The combination and concentration of therapeutic proteins is defined by the ratio of cells secreting different therapeutic proteins and/or by the gene expression ratio of the therapeutic proteins in the cells incorporated into the semi-permeable container. The therapeutic device can be used for treatments of various diseases and injuries for instance enhancement of wound healing and angiogenesis.

Abstract: The invention provides a polypeptide chain capable of forming a polyhedron by self-assembly, nanostructure polyhedra self-assembled from single polypeptide chains and a process for preparing self-assembled polyhedra from polypeptide comprising coiled-coil-forming segments in defined combination that can form dimers that form the edges of the polypeptide polyhedra within a single polypeptide chain. A defined sequence of coiled-coil-forming segments allow self-assembly into a defined polyhedral nanostructure such as a polypeptide tetrahedron.

Abstract: The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.

Abstract: The present invention relates to peptides with antimicrobial or endotoxin-neutralizing activity having the general formula (Xaa1)M-(Xaa2)0-Xaa3-(Xaa4)P-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.

Abstract: Compounds having a hydrophobic group with a group and capable of reacting with the cysteine residue for the binding to protein MD-2 are disclosed. The compounds are capable of covalently binding to MD-2, which can be either free or in the complex with other molecules. The compounds are capable of replacing other ligands or preventing a binding of other ligands, especially bacterial endotoxin (lipopolysaccharide-LPS), which can otherwise lead towards unwanted activation of the immune response and acute or chronic inflammatory diseases.